Beneficial Ownership Report · SCHEDULE 13G/A
Korro Bio, Inc.
KRRONASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G/A
primary_doc.xml
Amendment · This filing reports the amendment as submitted.
Subject company
- Company
- Korro Bio, Inc.
- Company CIK
- 0001703647
- Street
- 60 First Street, 2nd Floor, Suite 250
- City
- Cambridge
- State / country code
- MA
- Postal code
- 02141
Statement details
- Amendment number
- 1
- Security class
- Common Stock, par value $0.001 per share
- Event date
- 09/30/2026
- Rule designation
- Rule 13d-1(c)
Reporting person 1
- Name
- Venrock Healthcare Capital Partners III, L.P.
- Citizenship / organization
- DE
- Reporting person type
- PN
- Group designation
- a
- Aggregate amount owned
- 1,474,162.00
- Percent of class
- 9.9
- Sole voting power
- 0.00
- Shared voting power
- 1,474,162.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 1,474,162.00
Reporting person 2
- Name
- VHCP Co-Investment Holdings III, LLC
- Citizenship / organization
- DE
- Reporting person type
- OO
- Group designation
- a
- Aggregate amount owned
- 1,474,162.00
- Percent of class
- 9.9
- Sole voting power
- 0.00
- Shared voting power
- 1,474,162.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 1,474,162.00
Reporting person 3
- Name
- Venrock Healthcare Capital Partners EG, L.P.
- Citizenship / organization
- DE
- Reporting person type
- PN
- Group designation
- a
- Aggregate amount owned
- 1,474,162.00
- Percent of class
- 9.9
- Sole voting power
- 0.00
- Shared voting power
- 1,474,162.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 1,474,162.00
Reporting person 4
- Name
- VHCP Management III, LLC
- Citizenship / organization
- DE
- Reporting person type
- OO
- Group designation
- a
- Aggregate amount owned
- 1,474,162.00
- Percent of class
- 9.9
- Sole voting power
- 0.00
- Shared voting power
- 1,474,162.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 1,474,162.00
Reporting person 5
- Name
- VHCP Management EG, LLC
- Citizenship / organization
- DE
- Reporting person type
- OO
- Group designation
- a
- Aggregate amount owned
- 1,474,162.00
- Percent of class
- 9.9
- Sole voting power
- 0.00
- Shared voting power
- 1,474,162.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 1,474,162.00
Reporting person 6
- Name
- Nimish Shah
- Citizenship / organization
- X1
- Reporting person type
- IN
- Group designation
- a
- Aggregate amount owned
- 1,474,162.00
- Percent of class
- 9.9
- Sole voting power
- 0.00
- Shared voting power
- 1,474,162.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 1,474,162.00
Reporting person 7
- Name
- Bong Y. Koh
- Citizenship / organization
- X1
- Reporting person type
- IN
- Group designation
- a
- Aggregate amount owned
- 1,474,162.00
- Percent of class
- 9.9
- Sole voting power
- 0.00
- Shared voting power
- 1,474,162.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 1,474,162.00
Item 1
Issuer
Korro Bio, Inc.
Principal executive office address
60 First Street, 2nd Floor, Suite 250, Cambridge, MA, 02141.
Item 2
Citizenship
All of the entities were organized in Delaware. Shah and Koh are both United States citizens.
Filing person
The names of the persons filing this report (collectively, the "Reporting Persons") are: Venrock Healthcare Capital Partners III, L.P. ("VHCP III") VHCP Co-Investment Holdings III, LLC ("VHCP Co-Investment III") Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG") VHCP Management III, LLC ("VHCP Management III") VHCP Management EG, LLC ("VHCP Management EG") Nimish Shah ("Shah") Bong Koh ("Koh") The Reporting Persons are members of a group for the purposes of this Schedule 13G/A.
Principal business or residence address
New York Office: 7 Bryant Park, 23rd Floor New York, NY 10018 Palo Alto Office: 3340 Hillview Avenue Palo Alto, CA 94304
Item 3
Not applicable indication
Y
Item 4
Percent of class
Due to the Beneficial Ownership Blocker listed in the Pre-Funded Warrants, each Reporting Person's beneficial ownership percentage as of September 30, 2026 is 9.99%. Such percentage is based upon 13,725,646 shares of common stock outstanding as of September 30, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 5, 2026, and giving effect to Pre-Funded Warrants, to the extent exercisable within 60 days hereof, as referenced herein. Due to field limitations of the EDGAR filing system, the percentage listed in Row 11 of each Reporting Person's cover page has been rounded down to 9.9%.
Amount beneficially owned
Row 9 of each Reporting Person's cover page to this Schedule 13G/A sets forth the aggregate number of shares of common stock of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference. The Reporting Persons' ownership of the Issuer's securities consists of (i) 198,756 shares of common stock and pre-funded warrants (the "Pre-Funded Warrants") exercisable for up to 426,762 shares of common stock held by VHCP III; (ii) 19,895 shares of common stock and Pre-Funded Warrants exercisable for up to 42,597 shares of common stock held by VHCP Co-Investment III; and (iii) 224,780 shares of common stock and Pre-Funded Warrants exercisable for up to 2,176,406 shares of common stock held by held by VHCP EG. The Pre-Funded Warrants contain a provision (the "Beneficial Ownership Blocker"), which precludes the exercise of the Pre-Funded Warrants to the extent that, following exercise, VHCP III, VHCP Co-Investment III and VHCP EG, together with their affiliates and other attribution parties, would own more than 9.99% of the common stock outstanding of the Issuer. VHCP III, VHCP Co-Investment III and VHCP EG are currently prohibited from exercising the Pre-Funded Warrants to the extent that such exercise would result in beneficial ownership of more than 1,474,162 shares of common stock of the Issuer. VHCP Management III is the general partner of VHCP III and the manager of VHCP Co-Investment III. VHCP Management EG is the general partner of VHCP EG. Messrs. Shah and Koh are the voting members of VHCP Management III and VHCP Management EG.
Sole voting power
Row 5 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.
Shared voting power
Row 6 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.
Sole dispositive power
Row 7 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.
Shared dispositive power
Row 8 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.
Item 5
Not applicable indication
Y
Item 6
Not applicable indication
Y
Item 7
Not applicable indication
Y
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Exhibits
Exhibit 24.1 Power of Attorney for Bong Y. Koh (incorporated by reference to Exhibit 24.1 to the Reporting Persons' Schedule 13G filed with the SEC on March 17, 2026). Exhibit 24.2 Power of Attorney for Nimish P. Shah (incorporated by reference to Exhibit 24.2 to the Reporting Persons' Schedule 13G filed with the SEC on March 17, 2026). Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to the Reporting Persons' Schedule 13G filed with the SEC on March 17, 2026).
Signature 1
- Reporting person
- Venrock Healthcare Capital Partners III, L.P.
- Signed
- /s/ Sherman G. Souther
- Title
- By VHCP Management III, LLC, its General Partner, By Sherman G. Souther, Authorized Signatory
- Date
- 11/16/2026
Signature 2
- Reporting person
- VHCP Co-Investment Holdings III, LLC
- Signed
- /s/ Sherman G. Souther
- Title
- By VHCP Management III, LLC, its Manager, By Sherman G. Souther, Authorized Signatory
- Date
- 11/16/2026
Signature 3
- Reporting person
- Venrock Healthcare Capital Partners EG, L.P.
- Signed
- /s/ Sherman G. Souther
- Title
- By VHCP Management EG, LLC, its General Partner, By Sherman G. Souther, Authorized Signatory
- Date
- 11/16/2026
Signature 4
- Reporting person
- VHCP Management III, LLC
- Signed
- /s/ Sherman G. Souther
- Title
- By Sherman G. Souther, Authorized Signatory
- Date
- 11/16/2026
Signature 5
- Reporting person
- VHCP Management EG, LLC
- Signed
- /s/ Sherman G. Souther
- Title
- By Sherman G. Souther, Authorized Signatory
- Date
- 11/16/2026
Signature 6
- Reporting person
- Nimish Shah
- Signed
- /s/ Sherman G. Souther
- Title
- By Sherman G. Souther, Attorney-in-fact
- Date
- 11/16/2026
Signature 7
- Reporting person
- Bong Y. Koh
- Signed
- /s/ Sherman G. Souther
- Title
- By Sherman G. Souther, Attorney-in-fact
- Date
- 11/16/2026
Company context
Korro is a clinical-stage biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases. OPERA provides precise, tissue-directed delivery of RNA-editing oligonucleotides (REOs) that modify the targeted native mRNA transcript to repair or form a de-novo protein with enhanced functionality. The platform combines a suite of capabilities consisting of sophisticated knowledge of transcription biology through ADAR proteins (Adenosine Deaminases Acting on RNA), machine learning optimization of REOs, linker chemistry expertise, along with use of a highly targeted tissue-specific delivery methodology. As such, the OPERA platform has enabled Korro to generate and advance a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process, providing precise yet transient single base edits to produce therapeutic proteins with augmented activity versus its endogenous counterpart. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an REO-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary OPERA platform with precedented delivery modalities, including N-acetylgalactosamine (GalNAc) conjugated for delivery for subcutan
Current securities
Historical securities (1)
Recent company filings
- SCHEDULE 13G/A - filed by BALYASNY ASSET MANAGEMENT L.P. regarding Korro Bio, Inc.Nov 16, 2026
- 4 filingNov 13, 2026
- SCHEDULE 13G - filed by Adage Capital Management, L.P. regarding Korro Bio, Inc.Nov 12, 2026
- 10-Q filingNov 5, 2026
- Termination of a Material Definitive Agreement · Results of Operations and Financial ConditionNov 5, 2026